Clinical Trial Update: A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway [Phase 2]

View source ↗

Summary

Phase II, single-arm trial of poziotinib as salvage treatment for metastatic breast cancer with HER2/EGFR mutation or activated AR/EGFR pathway has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED